Review Article

Hypoxia: Progressive Multiple Myeloma and Its Therapy Resistance

Abstract

This study critically reviews the role of hypoxia in the progression of Multiple Myeloma (MM)and its therapy resistance. It explains the existence and role played by Hypoxia Inducible Factors (HIF) including HIF-1α and HIF-β in tumor (MM) progression. These HIF are key transcription factors of hypoxia and they aid the cellular adaptation of both normal and cancer cells to reduction in oxygen concentration. At initial stage of MM, the bone marrow environment sufficiently supports the growth and survival of the MM cells, but as the disease progresses and the plasma cells goes deeper into the bone marrow, they experience a more hypoxic condition. This then activates HIF-1 and HIF-2 which ultimately stimulates angiogenic factors. This is a description of the step by step approaches through which a review of Hypoxia: progressive multiple myeloma and its drug resistance was conducted using Google scholar and PubMed search engines to search articles published from 2000 to May 2020 using the following key words: hypoxia, progressive multiple myeloma, treatment resistance, hypoxia and multiple myeloma. This review suggests that agents capable of inhibiting the action of HIF’s, as well as those that would act specifically on the hypoxic zones will be helpful in minimizing/eliminating drug resistance and relapses in MM patients and would invariably improves the patient life expectancy.

World Health Organization. Introduction to Drug Utilization Research.
[Internet]. Oslo, Norway: WHO; 2003 [cited 2020 Dec 22]. Available from:
https://apps.who.int/iris/handle/10665/42627
2. Fallik B. The Academy of Managed Care Pharmacy’s concepts in managed
care pharmacy: prior authorization and the formulary exception process. J
Manag Care Pharm 2005;11(4):358-61.
3. Bergmans DC, Bonten MJ, Gaillard CA, et al. Indications for antibiotic
use in ICU patients: a one-year prospective surveillance. J Antimicrob
Chemother 1997;39(4):527-35.
4. Shoaei SD, Bagherzadeh A, Haghighi M, Shabani M. Vancomycin and five
broad-spectrum antibiotic utilization evaluation in an educational medical
center in one year. Journal of Pharmaceutical Care 2014;2(4):154-61
5. Soltani R, Khorvash F, Pazandeh F. Antimicrobial resistance pattern
of nosocomial infections at a referral teaching hospital. Journal of
Pharmaceutical Care 2020;8(1):26-34.
6. Singh N, Victor LY. Singh N, Yu VL. Rational empiric antibiotic prescription
in the ICU. Chest 2000;117(5):1496-9.
7. Hatcher JC, Dhillon R, Azadian B. Antibiotic resistance mechanisms in the
intensive care unit. J Intensive Care Soc 2012;13( 4):297-303.
8. Bisht R, Katiyar A, Singh R, Mittal P. Antibiotic resistance – A global issue
of concern. Asian J Pharm Clin Res 2009; 2(2): 34-9.
9. Hashemi S, Nasrollah A, Rajabi M. Irrational antibiotic prescribing: a local
issue or global concern? EXCLI J 2013;12:384-95.
10. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with
hospital-acquired and ventilator-associated pneumonia: 2016 clinical
practice guidelines by the Infectious Diseases Society of America and the
American Thoracic Society. Clin Infect Dis 2016;63(5):e61-e111.
11. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines
for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm
2013;70(3):195–283.
12. American Pharmacists Association (APhA). Drug Information Handbook:
A Clinically Relevant Resource for All Healthcare Professionals. 26th ed.
Ohio: Lexi-Comp; 2017-2018.
13. Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s
Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA:
Elsevier Saunders; 2015.
14. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors.
Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York:
McGraw-Hill Medical; 2017.
15. Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia AT, Black
D, Freedman DO, Kim K, Schwartz BS, editors. The Sanford guide to
antimicrobial therapy. Antimicrobial Therapy, Inc.; 2020.
16. Zarezadeh M, Shaterzadeh F, Abedini S, Raadabadi M. Evaluating pattern
of prescribing antibiotics in surgical wards of shahid rahnemon hospital
compared to standard methods in 2015. Journal of Shahid Sadoughi
University of Medical Sciences 2015;23(7):679-690.
17. Mahini S, Hayatshahi A, Torkamandi T, Gholami K, Javadi MR.
Carbapenem utilization in critically Ill patients. Journal of Pharmaceutical
Care 2013;1(4):141-144.
18. Rafati M.R, Sahraee S, Zamani Z, Irvash M. Antibiotics Usage in Intensive
Care Unit in Sari Bouali Sina Hospital. Journal of Mazandaran University of
Medical Sciences 2015; 24(122):12-22.
19. Kazmierczak KM, Biedenbach DJ, Hackel M, et al. Global dissemination
of blaKPC into bacterial species beyond Klebsiella pneumoniae and in
vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam.
Antimicrob Agents Chemother 2016;60(8):4490-500.
20. Lee C-R, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global
dissemination of carbapenemase-producing Klebsiella pneumoniae:
epidemiology, genetic context, treatment options, and detection methods.
Front Microbiol 2016;7:895.
21. Spyropoulou A, Papadimitriou-Olivgeris M, Bartzavali C, et al. A ten-year
surveillance study of carbapenemase-producing Klebsiella pneumoniae in a
tertiary care Greek university hospital: predominance of KPC-over VIM-or
NDM-producing isolates. J Med Microbiol 2016;65(3):240-6.
22. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A
review of its antibacterial activity, pharmacokinetic properties and clinical
effcacy. Drugs 1995;50(1):73-101.51
Obayi et al.
March 2021;9(1) jpc.tums.ac.ir
23. Naderi P, Shirani K, Soltani R, Khorvash F, Naji Esfahani SS. Meropenem
utilization evaluation in a referral teaching hospital in Iran. J Res Pharm
Pract 2018;7(2):83-7.
24. Yong D, Lee K, Yum JH, et al. Imipenem-EDTA disk method for differentiation
of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp.
and Acinetobacter spp. J Clin Microbiol 2002;40(10):3798-801.
25. Lee K, Ha GY, Shin BM, et al. Metallo-beta-lactamase-producing gramnegative bacilli in Korean Nationwide Surveillance of Antimicrobial
Resistance group hospitals in 2003: Continued prevalence of VIMproducing Pseudomonas spp. And increase of IMP-producing Acinetobacter
spp. Diagn Microbiol Infect Dis 2004;50(1):51-8.
26. Khan MU, Yousuf RI, Shoaib MH. Drug utilization evaluation of
meropenem and correlation of side effects with renal status of patients in a
teaching based hospital. Pak J Pharm Sci 2014;27(5 Spec no):1503-8.
27. Dew R.S, Radji M, Andalusia R. Evaluation of Antibiotic Use Among
Sepsis Patients in an Intensive Care Unit A cross-sectional study at a referral
hospital in Indonesia. Sultan Qaboos Univ Med J 2018;18(3):e367-e373.
Files
IssueVol 9, No 1 (Winter 2021) QRcode
SectionReview Article(s)
DOI https://doi.org/10.18502/jpc.v9i1.6036
Keywords
Hypoxia;Multiple Myeloma;Drug Resistance, Neoplasm

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Obayi O, Ogbonna E, Eleje C, Umerah N. Hypoxia: Progressive Multiple Myeloma and Its Therapy Resistance. J Pharm Care. 2021;9(1):45-51.